Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 28Cisplatin 25pembrolizumab 25Paclitaxel 22Nivolumab 20Gemcitabine 17Pemetrexed 15Rituximab 14Ipilimumab 13Cyclophosphamide 11Dexamethasone 11Fluorouracil 10durvalumab 10Capecitabine 9Docetaxel 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Sunitinib 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Erlotinib Hydrochloride × 1 year × Clear all
NCT02296125 2026-04-21

FLAURA

AstraZeneca

Phase 3 Completed
674 enrolled 21 charts 1 FDA
Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02411448 2026-01-16

RELAY

Eli Lilly and Company

Phase 3 Active not recruiting
545 enrolled 24 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡